Instrument Inactif

Autres langues PhaseBio Pharmaceuticals, Inc.

Actions

PHAS.Q

US7172241090

Autres langues

30/09/24	PhaseBio Pharmaceuticals, Inc. Went Out of Business
26/06/24	First Amended Combined Liquidation Plan and Disclousre Statement Approved on Final Basis for PhaseBio Pharmaceuticals, Inc.
13/05/24	Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc.
19/04/24	First Amended Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc.
07/02/24	Fifth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.
08/11/23	Fourth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.
03/10/23	PhaseBio Pharmaceuticals, Inc. Announces Resignation of Caroline Loewy as Member of the Board of Directors
07/09/23	Third Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.
01/08/23	Modified Combined Disclosure Statement Approved on Interim Basis for PhaseBio Pharmaceuticals, Inc.
10/07/23	Second Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.
07/07/23	Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc.
13/03/23	First Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.
17/02/23	First Motion for Exclusivity Period Extension Filed by PhaseBio Pharmaceuticals, Inc.
02/02/23	Motion for Asset Sale Approved for PhaseBio Pharmaceuticals, Inc.
02/02/23	Motion for Asset Sale Approved for PhaseBio Pharmaceuticals, Inc.
30/01/23	Motion for De Minimis Assets Sale Approved for PhaseBio Pharmaceuticals, Inc.
20/01/23	Notice of Selection of Auction and Asset Purchase Agreement Filed for Filed by PhaseBio Pharmaceuticals, Inc.
19/01/23	Chiesi Farmaceutici S.p.A. cancelled the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab.
13/01/23	Notice of Rescheduled Auction Filed by PhaseBio Pharmaceuticals, Inc.
31/12/22	Motion for Asset Sale Approved for PhaseBio Pharmaceuticals, Inc.
22/12/22	Notice of Extention of Bidding Procedures Deadlines Filed by PhaseBio Pharmaceuticals, Inc.
22/12/22	Notice of Rescheduled Auction Filed by PhaseBio Pharmaceuticals, Inc.
02/12/22	PhaseBio Pharmaceuticals, Inc. Announces Executive Changes
28/11/22	Bidding Procedure Approved for PhaseBio Pharmaceuticals, Inc.
23/11/22	PhaseBio Pharmaceuticals, Inc. Announces Resignation of John P. Sharp as Chief Financial Officer, Effective November 30, 2022